Clinical Trials Browser

NCT05348876 2026-03-19

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Phase 4 Recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT06282588 2026-03-19

THUNDER

Phase 2/3 Recruiting

493 enrolled

Genitourinary

Prostatic Neoplasms

NCT07103018 2026-03-16

STRIKE-001

Phase 1 Recruiting

144 enrolled

Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Clinical Trials

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

THUNDER

STRIKE-001

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

ASCERTAIN

AMX-500

SOGUG-PRINCIS

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Double-DARE

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

EvoPAR-PR01

ENGAGER-PSMA-01

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

TRIPLE-SWITCH

DIVINE

PRO-MIND

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

PICASSO

ProBio

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

PSA-DEEP02

PEACE8

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

DAROTAXEL

ALADDIN